Hoth Therapeutics (Hoth Therapeutics) Asset Impairment Charge : $0.00 Mil (TTM As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Hoth Therapeutics Asset Impairment Charge?

Hoth Therapeutics's Asset Impairment Charge for the three months ended in Mar. 2024 was $0.00 Mil. Its Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2024 was $0.00 Mil.

Hoth Therapeutics Asset Impairment Charge Historical Data

The historical data trend for Hoth Therapeutics's Asset Impairment Charge can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hoth Therapeutics Asset Impairment Charge Chart

Hoth Therapeutics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Asset Impairment Charge

Get a 7-Day Free Trial

Hoth Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Asset Impairment Charge	Get a 7-Day Free Trial															-	-	-	-	-

Hoth Therapeutics Asset Impairment Charge Calculation

Asset Impairment Charge is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

Asset Impairment Charge for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Hoth Therapeutics Asset Impairment Charge Related Terms

Thank you for viewing the detailed overview of Hoth Therapeutics's Asset Impairment Charge provided by GuruFocus.com. Please click on the following links to see related term pages.

Hoth Therapeutics (Hoth Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hoth Therapeutics Inc (NAS:HOTH) » Definitions » Asset Impairment Charge

Comparable Companies

Traded in Other Exchanges

N/A

Address

1 Rockefeller Plaza, Suite 1039, New York, NY, USA, 10020

Website

https://www.hoththerapeutics.com

Hoth Therapeutics Inc is a development-stage biopharmaceutical company. It is focused on targeted therapeutics for patients suffering from conditions such as atopic dermatitis, also known as eczema, chronic wounds, psoriasis, asthma, and acne. The company owns the BioLexa Platform which combines an FDA-approved zinc chelator with one or more approved antibiotics in a topical dosage form to address unchecked eczema flare-ups.

Executives

Jeff Pavell	director	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Robb Knie	director, officer: CEO and President	C/O INVENTERGY GLOBAL, INC., 900 EAST HAMILTON AVENUE SUITE 180, CAMPBELL CA 95008
Stefanie Johns	officer: Chief Scientific Officer	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Anthony Hayes	director	1796 SHADY LANE, COLUMBIA SC 29206
Wayne Linsley	director	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Graig Springer	director	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
Spherix Inc	10 percent owner	725 FIFTH AVENUE, 22ND FLOOR, NEW YORK NY 10022
Vadim Mats	director	285 GRAND AVENUE, ENGLEWOOD NJ 07631
Rice Kenneth L Jr	director	C/O 85 MAIN STREET, HOPKINTON MA 01748
David Sarnoff	director	1 ROCKEFELLER PLAZA, SUITE 1039, NEW YORK NY 10020
David S. Briones	officer: Chief Financial Officer	C/O PETRO RIVER OIL COMPANY, 1980 POST OAK BLVD., SUITE 2020, HOUSTON TX 77056
Matthew D. Eitner	10 percent owner	44 BRAMS HILL DRIVE, MAHWAH NJ 07430
Kevin Jess Poor	10 percent owner	750 BEULAHS LANE, IDAHO FALLS ID 83401
James P. Ahern	10 percent owner	20 WEST 64TH STREET, APT 18RS, NEW YORK NY 10023